Clinical Pathways

A newly published retrospective study in The Annals of Thoracic Surgery found that lobectomy improved survival in patients with early-stage lung cancer compared with SBRT.

A new tool developed by the Agency for Healthcare Research and Quality and the ECRI Institute will assess the extent to which a guideline adheres to the Institute of Medicine’s (IOM) standards for trustworthy evidence-based clinical guidelines.

Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine.

Documenting when a patient falls outside of a recommended pathway has the dual benefits of improving the algorithm and helping a provider get reimbursed faster, explained Torrie K. Fields, MPH, senior program manager of Palliative Care Program Design & Implementation for Blue Shield of California.

High chemotherapy costs are only one reason for the rising cost of cancer care. End-of-life care and hospitalizations are within an oncologist's control and must be better managed given new reimbursement structures.

Reimbursement policy has been a driver of change in the way hospitals handle heart failure patients.

Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.

With the risk of upgrade of flat epithelial atypia to malignancy is low, surveillance rather than surgery is a reasonable option for patients, according to a study.

The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.

Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.

After a study reported that physicians who authored dermatology clinical guidelines didn't always fully disclose financial conflicts of interest, the American Academy of Dermatology urged the public to view the findings with caution.

October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.

A new paper in JCO Precision Oncology evaluated the impact of the support provided by a decision support team on clinical decision making and trial enrollment.

Physicians across different institutes who have been involved in clinical trials of chimeric antigen receptor (CAR) T cells in B-cell lymphomas have developed a guideline for monitoring and managing the symptoms associated with this treatment.

Cabazitaxel can now be used at a dose of 20 mg/m2 every 3 weeks in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have received a docetaxel-based treatment regimen.

Patients with relapsed follicular lymphoma now have a new treatment option: copanlisib, a kinase inhibitor that was recently approved through the FDA’s accelerated approval process.

The FDA has approved bevacizumab-awwb (Mvasi) as a treatment for multiple cancers. The drug has been approved as a biosimilar to its reference biologic, bevacizumab (Avastin), but it has not been approved as an interchangeable product.